Clinical trials: Pregnancy in Diabetic
Diabetic Kidney Disease, Type 1 Diabetes
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage kidney disease, affecting 25-40% of type 1 diabetes (T1D) patients and 5-40% of type 2 diabetes (T2D) patients.
- Trial name
- NCT06532682
- Testing
- dapagliflozin, ACE inhibitor
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diabetic Nephropathy
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
The primary objective of this study is to evaluate the efficacy of two different doses of Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic nephropathy.
- Trial name
- NCT00734253
- Testing
- Pyridoxamine Dihydrochloride
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- NephroGenex, Inc.
Diabetic Kidney Disease
Impact of Multidisciplinary Self-care Management of Diabetic Nephropathy on Quality of Life, Self-care Behavior, Glycemic Control, and Renal Function.
Diabetic Kidney Disease (DKD) is becoming a global health concern that affects largely the elderly population. Despite advances in pharmacological and management strategies, DKD remain associated with high morbidity and…
- Trial name
- NCT01967901
- Testing
- Self-care management program
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- University of Applied Sciences of Western Switzerland
Diabetic Kidney Disease, Diabetic Nephropathies
Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a frequent microvascular complication in individuals with type 2 diabetes mellitus (T2DM) and a major cause of chronic kidney failure worldwide.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathies, Type 2 Diabetes Mellitus, Albuminuria
- Trial name
- NCT07773467
- Volunteers
- 120 people
- Sponsor
- Assiut University
Diabetic Nephropathy
Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value
Expression analysis of urinary exosome miR-136-5p in type 2 diabetic nephropathy and evaluation of its clinical diagnostic value
- Trial name
- NCT06123871
- Testing
- Grouping based on previous laboratory results, no intervention.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yipeng Liu
Chronic Kidney Disease
Therapeutic Drug Use for CKD Patients
Chronic kidney disease (CKD), characterized as renal dysfunction, is recognized as a major public health problem with high morbidity and mortality worldwide.
- Trial name
- NCT05818995
- Testing
- angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Qianfoshan Hospital
Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy
Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes
The effects of consuming non-nutritive sweeteners (NNS) during pregnancy and lactation on infant obesity and cardiometabolic disease risk are not well understood.
- Conditions
- Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy, Non-nutritive Sweeteners Consumption in Pregnancy and/or Lactation
- Trial name
- NCT06548828
- Testing
- NNS Restriction Intervention, Control Intervention
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- George Washington University
Type 1 Diabetes Mellitus With Diabetic Nephropathy
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease.
- Trial name
- peeDIAB2 (NCT02164279)
- Testing
- Urinary sample collection
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Toulouse
Gestational Diabetes Mellitus (GDM)
Insulin Resistance in Gestational Diabetes Mellitus
This prospective cohort study investigates glycaemic variability, assessed by continuous glucose monitoring (CGM), in pregnant women with gestational diabetes mellitus (GDM) and its association with fetal growth and related…
- Trial name
- IRIS (NCT07231341)
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Chronic Renal Failure
Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy
Diabetes kidney disease is a leading cause for end stage renal disease in the western world. To date no treatment that can reverse renal damage exists.
- Trial name
- NCT03376282
- Testing
- Hyperbaric Oxygen oxygen therapy (HBOT)
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Assaf-Harofeh Medical Center
Diabetic Nephropathy, Diabetes Mellitus
Soy Protein in Early Diabetic Nephropathy
Diabetic nephropathy is a frequent cause of end-stage renal disease. Reduction of dietary protein has been used to slow down renal disease progression, but patients are often unwilling to make these dietary changes.
- Trial name
- NCT00067678
- Testing
- soy protein
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Diabetes Mellitus, Type I, Diabetic Nephropathy
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension and diabetic nephropathy.
- Trial name
- NCT00118976
- Testing
- Lisinopril
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes
Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4 inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
- Trial name
- RENALIS (NCT02106104)
- Testing
- Linagliptin 5 mg QD (N=24), Glimepiride 1 mg QD (N=24)
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Amsterdam UMC, location VUmc
End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis
Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR
Phase IV post-marketing study to evaluate the effect of Extraneal on the HOMA index in non-diabetic CAPD patients over the long-dwell exchange.
- Trial name
- ECOS (NCT01093547)
- Testing
- Blood samples, Measure of peritoneal ultrafiltrates
- Where
- Colombia
- Sponsor
- Vantive Health LLC
Diabetic Nephropathies
Comprehensive Management of Diabetic Patients With Renal Impairment : Impact on Blood Pressure and Glycemic Control
Diabetes is the leading cause of end-stage renal disease in developed countries. Hypertension and metabolic control are known to affect the progression of renal deficiency and patient's outcome.
- Trial name
- NCT00306436
- Testing
- comprehensive management
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- FineCaRe (NCT07026539)
- Testing
- Finerenone (BAY 94-8862)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Chronic Kidney Disease, Diabetic Nephropathy
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Prospective, randomized, double-blind, placebo controlled, 12-week, multicenter study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets compared to placebo in…
- Trial name
- NCT01424319
- Testing
- Atrasentan low dose group, Atrasentan high dose group
- Where
- 18 sites in Japan
- Volunteers
- 58 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Nephropathy
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which…
- Trial name
- NCT00240019
- Testing
- Addition of furosemide 20 mg oral bid to baseline regimen
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Diabetic Nephropathy, Chronic Kidney Disease
Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
Diabetic nephropathy has become the single most frequent cause of end-stage renal disease. On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these…
- Conditions
- Diabetic Nephropathy, Chronic Kidney Disease, Diabetes Type 2
- Trial name
- NCT00556465
- Testing
- N-acetylcysteine
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM)
RCT Glargine vs NPH for Treatment of DM in Pregnancy
We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy.
- Conditions
- Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
- Trial name
- NCT06619301
- Testing
- Insulin glargine, insulin NPH
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Loyola University